BIOMAT Database Logo BIOMAT Database Logo

Octreotide acetate long-acting release in treatment of pancreatic neuroendocrine tumors. 2009

Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010190 Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). Cancer of Pancreas,Pancreatic Cancer,Cancer of the Pancreas,Neoplasms, Pancreatic,Pancreas Cancer,Pancreas Neoplasms,Pancreatic Acinar Carcinoma,Pancreatic Carcinoma,Acinar Carcinoma, Pancreatic,Acinar Carcinomas, Pancreatic,Cancer, Pancreas,Cancer, Pancreatic,Cancers, Pancreas,Cancers, Pancreatic,Carcinoma, Pancreatic,Carcinoma, Pancreatic Acinar,Carcinomas, Pancreatic,Carcinomas, Pancreatic Acinar,Neoplasm, Pancreas,Neoplasm, Pancreatic,Neoplasms, Pancreas,Pancreas Cancers,Pancreas Neoplasm,Pancreatic Acinar Carcinomas,Pancreatic Cancers,Pancreatic Carcinomas,Pancreatic Neoplasm
D011859 Radiography Examination of any part of the body for diagnostic purposes by means of X-RAYS or GAMMA RAYS, recording the image on a sensitized surface (such as photographic film). Radiology, Diagnostic X-Ray,Roentgenography,X-Ray, Diagnostic,Diagnostic X-Ray,Diagnostic X-Ray Radiology,X-Ray Radiology, Diagnostic,Diagnostic X Ray,Diagnostic X Ray Radiology,Diagnostic X-Rays,Radiology, Diagnostic X Ray,X Ray Radiology, Diagnostic,X Ray, Diagnostic,X-Rays, Diagnostic
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995
D018358 Neuroendocrine Tumors Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. Neuroendocrine Tumor,Tumor, Neuroendocrine,Tumors, Neuroendocrine

Related Publications

Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
September 2000, Annals of oncology : official journal of the European Society for Medical Oncology,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Prescribing Characteristics of Octreotide Immediate-Release and Long-Acting Release in Patients with Neuroendocrine Tumors.
June 2023, The oncologist,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Treatment with Lanreotide Depot Following Octreotide Long-Acting Release Among Patients with Gastroenteropancreatic Neuroendocrine Tumors.
January 2018, Journal of pancreatic cancer,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Improved survival with higher doses of octreotide long-acting release in gastroenteropancreatic neuroendocrine tumors.
August 2018, Medical oncology (Northwood, London, England),
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Octreotide long-acting repeatable in the treatment of neuroendocrine tumors: patient selection and perspectives.
January 2017, Biologics : targets & therapy,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors.
November 2017, American health & drug benefits,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Outcomes of first-line long-acting octreotide treatment in non-functional, advanced gastroenteropancreatic neuroendocrine tumors.
January 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
January 2013, Neuroendocrinology,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Successful treatment of congenital hyperinsulinism with long-acting release octreotide.
February 2012, European journal of endocrinology,
Shi Zhang, and Yu-xiu Li, and Nai-shi Li, and Wen-hui Li, and Hui-juan Zhu, and Feng Gu, and Heng Wang
Hypercalcemia appeared in a patient with glucagonoma treated with octreotide acetate long-acting release.
September 2012, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
Copied contents to your clipboard!